News

The abnormal alpha-synuclein characteristic of Parkinson’s disease interacts with the prion protein PrP, initiating a series of events that culminate in neuronal degeneration and cognitive impairment, a European study found. But a drug from the caffeine family prevented this interaction, reversing degeneration and Parkinson’s symptoms in mice. The study, “…

Researchers reported a significant relationship between sleep disturbances in Parkinson’s disease (PD) patients and their disease-related disability, including tremors, impaired posture, and slowed movement. Also, excessive daytime sleepiness and REM sleep behavior disorder were more common in PD patients than control subjects. The study, “…

Poor adherence to antidepressants is correlated with an increase in all-cause mortality in patients with Parkinson’s disease (PD), a new study suggests. Based on the findings, the study’s authors recommend that neurologists, psychiatrists, and primary-care physicians prioritize the use of, and adherence to, antidepressants as indicated. The study, “…

Recent research shows that the Parkinson’s disease (PD) protein, alpha-synuclein, blocks pro-survival signals from an important brain growth factor. These findings provide new reasons why neurons degenerate and are lost in patients with PD. The finding, “TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic celldeath in Parkinson’s…

Infection with the brain parasite Toxoplasma gondii may increase the likelihood for certain brain disorders, including Parkinson’s and Alzheimer’s disease, a systematic analysis suggests. The study, “Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer,” was published in the journal Scientific Reports. Over two…

A new algorithm can accurately predict cognitive decline in Parkinson’s disease patients within 10 years of disease onset, a study shows. The study, “Prediction of cognition in Parkinson’s disease with a clinical–genetic score: a longitudinal analysis of nine cohorts,” was published in the journal…

AC Immune has developed antibodies against two proteins that are key players in the neurodegeneration underlying Parkinson’s and other neurological diseases. The Swiss biopharmaceutical company used its proprietary SupraAntigen platform to create the next-generation antibodies, which target abnormal versions of the alpha-synuclein and TDP-43 proteins. AC Immune has already used the platform to produce…